Zacks Investment Ideas feature highlights: Novo Nordisk
For Immediate Release
Chicago, IL – December 15, 2022 – Today, Zacks Investment Ideas feature highlights Novo Nordisk A/S NVO.
Simplify Your Investing Process Using This Top-Down Approach
“Life is really simple, but men insist on making it complicated.” - Confucius
In investing, as in life, we want to simplify our process as much as possible. I’ve found that the more indicators and nuances that go into a strategy, the less likely that strategy will perform well over the long-term. Anyone can backtest a strategy and massage the data to create the appearance of outperformance.
The true test, however, is how a strategy performs in the real world, in real-time, that spans several market cycles. This year it’s been even more important to have a sound approach that limits losses yet still finds ways to take advantage of the market’s volatility.
While major headwinds still remain for the economy, including lingering (although decelerating) inflation and slowing earnings growth, the market is forward-looking and much of the damage in this bear market may already have occurred. With positive seasonality underway, a Fed that is beginning to slow the pace of rate hikes, and both a falling dollar and treasury yields, the signs are pointing to continued strength in equities off the October lows.
Letting the market guide us rather than trying to predict what will happen is normally the most prudent course of action. The market is the horse and we are simply the caboose, unable to direct or alter its direction. For now, it’s best to target stocks that have displayed immunity to the year’s volatility and are still showing positive trends.
The Zacks Large Cap Pharmaceuticals industry is currently ranked in the top 33% out of approximately 250 industries. Because it is ranked in the top half of all Zacks Ranked Industries, we expect this group to outperform the market over the next 3 to 6 months.
Digging a bit deeper, this group has widely outperformed the market this year with a greater than 15% return.
Despite the impressive price performance, the Zacks Large Cap Pharmaceuticals industry remains relatively undervalued.
Quantitative research studies have shown that approximately half of a stock’s future price movement can be attributed to its industry group. By focusing on stocks within the top industries, we can dramatically improve our odds of success. Let’s take a deeper look at a top-performing stock within this highly-rated industry.
Novo Nordisk A/S
Novo Nordisk is a global healthcare company that engages in the research, development, manufacturing, and marketing of pharmaceutical products. The company’s Diabetes and Obesity care segment provides insulin, antidiabetic, obesity, and other chronic disease products. NVO’s Biopharmaceuticals segment offers products in the areas of hemophilia, growth disorders, and hormone replacement therapy.
NVO maintains a strong presence in the Diabetes care market with a broad portfolio, improving its market share to nearly 32% in the last 12 months. Drug sales have been gaining momentum, and label expansion of existing drugs is likely to boost sales further in the coming quarters. In addition, NVO has witnessed encouraging pipeline progress through its developmental drug phase process.
Novo Nordisk has surpassed earnings estimates in three of the past four quarters, with an average surprise of 3.09%. The healthcare company most recently announced Q3 earnings results last month of $0.86/share, a 2.38% beat over consensus estimates. Sales of $6.17 billion also beat projections and have been steadily trending upward. NVO is expected to grow revenues by 18.8% to $27.23 billion next year. Earnings are projected to rise 22.53% to $3.97 per share.
NVO stock has been on a tear, as shares have more than tripled in the past four years while showing relatively little volatility. This year, the stock has climbed more than 21%.
Novo Nordisk has bucked the market’s downtrend, rewarding shareholders with substantial gains. Given an uncertain economic environment heading into next year, NVO investors have plenty of reasons to remain bullish.
Why Haven’t You Looked at Zacks' Top Stocks?
Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novo Nordisk AS (NVO) : Free Stock Analysis Report
